Proceedings of the National Academy of Sciences

OCT 20, 2026 · JOURNAL ARTICLE

PLD1-driven oncogenic secretion creates a therapeutic vulnerability in chromosome 3q–amplified NSCLC

Proceedings of the National Academy of Sciences

Chromosome 3q (3q) amplification is a frequent event in non–small cell lung cancer (NSCLC) and other cancer types, yet therapeutic strategies targeting oncogenic drivers within thi

OCT 15, 2026 · JOURNAL ARTICLE

LEAP2 mediates long-term inhibition of orexigenic neurons of the hypothalamus in mice

Proceedings of the National Academy of Sciences

Liver-expressed antimicrobial peptide 2 (LEAP2) acts via the growth hormone secretagogue receptor (GHSR) to reduce food intake, yet the central mechanisms underlying its anorectic

SEP 30, 2026 · JOURNAL ARTICLE

Targeted extracellular degradation of LRP8 promotes ferroptosis in cancer cells

Proceedings of the National Academy of Sciences

Tumor reliance on antioxidant defenses creates a vulnerability to ferroptosis, yet strategies to therapeutically disable these systems remain limited. Here, we identify targeted de

SEP 25, 2026 · JOURNAL ARTICLE

An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss

Proceedings of the National Academy of Sciences

Current obesity therapies reduce weight but often fail to preserve lean mass or sustain metabolic benefit. Glucagon-like peptide-1 receptor agonists (GLP-1RA) improve obesity-assoc

SEP 24, 2026 · JOURNAL ARTICLE

Mitochondrial NADP(H)–dependent de novo dTMP biosynthesis counteracts the cytotoxicity of PARP inhibitors

Proceedings of the National Academy of Sciences

PARP inhibitors (PARPis), known to elicit mitochondrial protection in nononcological diseases by elevating the cellular NAD + pool, exhibit potent cytotoxicity in selected human ca

SEP 17, 2026 · JOURNAL ARTICLE

Promotion of long-term health in early life

Proceedings of the National Academy of Sciences

Noncommunicable chronic diseases (NCDs) are on the rise in high-income countries, leading to substantial morbidity and mortality and contributing to increased resource demands and

SEP 16, 2026 · JOURNAL ARTICLE

RHAMM drives formation of polyploid cancer cells and confers resistance to ER-targeted therapy in breast cancer

Proceedings of the National Academy of Sciences

Endocrine resistance in ER + breast cancer remains a major clinical challenge. Here, we identify RHAMM as a key driver of resistance by orchestrating polyploid cancer cell (PCC) fo

SEP 9, 2026 · JOURNAL ARTICLE

Minimal-length CAG repeats in AR define a hyperactive AR–LSD1 axis driving metabolic reprogramming in prostate cancer

Proceedings of the National Academy of Sciences

Cell line study identifying a mechanistic link between AR CAG repeat polymorphism and metabolic reprogramming; lacks in vivo validation, patient outcome data, or clinical endpoint evidence.